CHU [CHINA UNICOM (HONG KONG)] 6-K: (Original Filing)

[3 3 5 1 Annual Results Announcement of China Unicom (Hong Kong) Limited for the year ended December 31, 2014. • • changes in the PRC telecommunications industry resulting from the issuance of 3G and 4G licenses by the central government of the PRC; • effects of tariff reduction and other policy initiatives from the relevant PRC government authorities;]

By | 2016-03-15T01:46:18+00:00 March 4th, 2015|Categories: Chinese Stocks, CHU, SEC Original|Tags: , , , , , |0 Comments

CHU [CHINA UNICOM (HONG KONG)] 6-K: 3 3 5 1 Annual Results Announcement of

[3 3 5 1 Annual Results Announcement of China Unicom (Hong Kong) Limited for the year ended December 31, 2014. • • changes in the PRC telecommunications industry resulting from the issuance of 3G and 4G licenses by the central government of the PRC; • effects of tariff reduction and other policy initiatives from the relevant PRC government authorities;]

By | 2016-03-15T01:48:38+00:00 March 4th, 2015|Categories: Chinese Stocks, CHU, Webplus ver|Tags: , , , , , |0 Comments

SOL [ReneSola] 6-K: (Original Filing)

[ReneSola Ltd Announces Fourth Quarter and Full Year 2014 Results JIASHAN, China, March 4, 2015 Fourth Quarter 2014 Financial and Operating Highlights · Total solar module shipments were 488.4 megawatts (“MW”), exceeding previous guidance and representing an increase of 5.7% from Q3 2014. Total solar wafer and module shipments in Q4 2014 were 744.3 MW, representing an increase of 12.1%] []

By | 2016-03-19T05:09:30+00:00 March 4th, 2015|Categories: Chinese Stocks, SEC Original, SOL|Tags: , , , , , |0 Comments

SOL [ReneSola] 6-K: ReneSola Ltd Announces Fourth Quarter and Full Year

[ReneSola Ltd Announces Fourth Quarter and Full Year 2014 Results JIASHAN, China, March 4, 2015 Fourth Quarter 2014 Financial and Operating Highlights · Total solar module shipments were 488.4 megawatts (“MW”), exceeding previous guidance and representing an increase of 5.7% from Q3 2014. Total solar wafer and module shipments in Q4 2014 were 744.3 MW, representing an increase of 12.1%] []

By | 2016-03-19T05:11:39+00:00 March 4th, 2015|Categories: Chinese Stocks, SOL, Webplus ver|Tags: , , , , , |0 Comments

KANG [iKang Healthcare] 6-K: (Original Filing)

[Press Release iKang Announces Two Acquisitions in Tianjin to Continue Its Nationwide Network Expansion BEIJING, March 3, 2015 (GLOBE NEWSWIRE) — iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), today announced that it had completed the acquisitions of Tianjin Hexi Kangmeng Hezhong Clinic Co., Ltd. and Tianjin Hedong District REMAHO Clinic Co., Ltd., which were set up in 2008] [FORM 6-K IKANG HEALTHCARE GROUP, INC. B-6F, Shimao Tower 92A Jianguo Road Chaoyang District, Beijing 100022 People’s Republic of China Form 20-F x Form 40-F o o o IKANG HEALTHCARE GROUP, INC.]

KANG [iKang Healthcare] 6-K: Press Release iKang Announces Two Acquisitions in Tianjin

[Press Release iKang Announces Two Acquisitions in Tianjin to Continue Its Nationwide Network Expansion BEIJING, March 3, 2015 (GLOBE NEWSWIRE) — iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq:KANG), today announced that it had completed the acquisitions of Tianjin Hexi Kangmeng Hezhong Clinic Co., Ltd. and Tianjin Hedong District REMAHO Clinic Co., Ltd., which were set up in 2008] [FORM 6-K IKANG HEALTHCARE GROUP, INC. B-6F, Shimao Tower 92A Jianguo Road Chaoyang District, Beijing 100022 People’s Republic of China Form 20-F x Form 40-F o o o IKANG HEALTHCARE GROUP, INC.]

CBPO [China Biologic Products] 8-K: (Original Filing)

[CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company Mr. Min Fang Director THIS AGREEMENT (The “ BACKGROUND The Board of Directors of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director perform the duties of a director and the Director desires to be so appointed] [FOR RELEASE March 4, 2015 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4Q14 Total Sales Up 36.2% to 58.0 Million / FY14 Total Sales Up 19.6% to $243.3 Million -- -- -- 4Q14 Operating Margin Up 470 Basis Points to 34.0% / FY14 Operating Margin Up 300 Basis Points to 45.7% -- -- 4Q14] []

CBPO [China Biologic Products] 8-K: CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company

[CHINA BIOLOGIC PRODUCTS, INC. DIRECTOR AGREEMENT Agreement Company Mr. Min Fang Director THIS AGREEMENT (The “ BACKGROUND The Board of Directors of the Company desires to appoint the Director to fill an existing vacancy due to resignation of Mr. Dai Feng and to have the Director perform the duties of a director and the Director desires to be so appointed] [FOR RELEASE March 4, 2015 China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4Q14 Total Sales Up 36.2% to 58.0 Million / FY14 Total Sales Up 19.6% to $243.3 Million -- -- -- 4Q14 Operating Margin Up 470 Basis Points to 34.0% / FY14 Operating Margin Up 300 Basis Points to 45.7% -- -- 4Q14] []

Skip to toolbar